D.E. Shaw & Co’s Nektar Therapeutics NKTR Stock Holding History

D.E. Shaw & Co’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,679	Closed	-$78.3K	–	4592
2025 Q1	$78.3K	Sell	7,679 -4,001	-34%	-$52.3K	﹤0.01%	4041
2024 Q4	$163K	Buy	11,680 +8,498	+267%	+$150K	﹤0.01%	4114
2024 Q3	$62.1K	Sell	3,182 -19,928	-86%	-$380K	﹤0.01%	4287
2024 Q2	$430K	Sell	23,110 -146,823	-86%	-$3.09M	﹤0.01%	3721
2024 Q1	$2.38M	Sell	169,933 -103,323	-38%	-$1.08M	﹤0.01%	2489
2023 Q4	$2.32M	Sell	273,256 -134,946	-33%	-$1.02M	﹤0.01%	2555
2023 Q3	$3.65M	Sell	408,202 -201,953	-33%	-$1.94M	﹤0.01%	2104
2023 Q2	$5.26M	Buy	610,155 +390,044	+177%	+$4.16M	0.01%	1829
2023 Q1	$2.32M	Buy	220,111 +144,917	+193%	+$4.38M	﹤0.01%	2582
2022 Q4	$2.55M	Buy	75,194 +29,933	+66%	+$1.45M	﹤0.01%	2726
2022 Q3	$2.17M	Buy	45,261 +8,531	+23%	+$508K	﹤0.01%	2927
2022 Q2	$2.09M	Sell	36,730 -6,045	-14%	-$381K	﹤0.01%	3023
2022 Q1	$3.46M	Buy	42,775 +16,959	+66%	+$2.51M	﹤0.01%	2745
2021 Q4	$5.23M	Sell	25,816 -1,877	-7%	-$407K	﹤0.01%	2323
2021 Q3	$7.46M	Buy	27,693 +5,967	+27%	+$1.43M	0.01%	1751
2021 Q2	$5.59M	Sell	21,726 -5,935	-21%	-$1.64M	﹤0.01%	1942
2021 Q1	$8.3M	Sell	27,661 -38,140	-58%	-$11.9M	0.01%	1486
2020 Q4	$16.8M	Buy	65,801 +29,760	+83%	+$7.69M	0.02%	1048
2020 Q3	$8.97M	Buy	36,041 +1,159	+3%	+$365K	0.01%	1311
2020 Q2	$12.1M	Buy	34,882 +33,840	+3,248%	+$10.6M	0.01%	1076
2020 Q1	$279K	Sell	1,042 -5,329	-84%	-$1.65M	﹤0.01%	3505
2019 Q4	$2.06M	Sell	6,371 -1,561	-20%	-$453K	﹤0.01%	2439
2019 Q3	$2.17M	Sell	7,932 -14,429	-65%	-$5.29M	﹤0.01%	2277
2019 Q2	$11.9M	Sell	22,361 -58,520	-72%	-$29.3M	0.01%	1037
2019 Q1	$40.8M	Buy	80,881 +28,239	+54%	+$16.7M	0.05%	437
2018 Q4	$26M	Buy	52,642 +41,695	+381%	+$25.2M	0.04%	596
2018 Q3	$10M	Sell	10,947 -12,886	-54%	-$11M	0.01%	1119
2018 Q2	$17.5M	Sell	23,833 -24,845	-51%	-$28.6M	0.02%	787
2018 Q1	$77.6M	Buy	48,678 +48,418	+18,622%	+$62.4M	0.11%	236
2017 Q4	$232K	Sell	260 -1,183	-82%	-$700K	﹤0.01%	3365
2017 Q3	$519K	Sell	1,443 -7,610	-84%	-$2.38M	﹤0.01%	2888
2017 Q2	$2.65M	Buy	9,053 +310	+4%	+$89.6K	﹤0.01%	1792
2017 Q1	$3.08M	Sell	8,743 -4,043	-32%	-$909K	0.01%	1590
2016 Q4	$2.35M	Buy	12,786 +6,081	+91%	+$1.24M	﹤0.01%	1875
2016 Q3	$1.73M	Sell	6,705 -3,831	-36%	-$986K	﹤0.01%	2031
2016 Q2	$2.25M	Sell	10,536 -38,410	-78%	-$8.59M	﹤0.01%	1847
2016 Q1	$10.1M	Buy	48,946 +24,323	+99%	+$4.67M	0.02%	862
2015 Q4	$6.22M	Buy	+24,623	New	+$5.06M	0.01%	1260
2015 Q3	–	Sell	-35,045	Closed	-$6.58M	–	3837
2015 Q2	$6.58M	Sell	35,045 -14,867	-30%	-$2.56M	0.01%	1280
2015 Q1	$8.24M	Buy	49,912 +23,350	+88%	+$4.8M	0.01%	1075
2014 Q4	$6.18M	Buy	26,562 +24,109	+983%	+$5.15M	0.01%	1412
2014 Q3	$444K	Sell	2,453 -1,171	-32%	-$224K	﹤0.01%	3442
2014 Q2	$697K	Sell	3,624 -6,475	-64%	-$1.15M	﹤0.01%	3249
2014 Q1	$1.84M	Sell	10,099 -33,594	-77%	-$6.65M	﹤0.01%	2476
2013 Q4	$7.44M	Sell	43,693 -24,956	-36%	-$4.02M	0.01%	1358
2013 Q3	$10.8M	Buy	68,649 +36,600	+114%	+$6.77M	0.02%	946
2013 Q2	$5.55M	Buy	+32,049	New	+$4.92M	0.01%	1278

Other funds holding NKTR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co's NKTR Position: Q2 2025 in Review

D.E. Shaw & Co sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 7,679 shares — an estimated $78.3K sold.

D.E. Shaw & Co first reported a position in NKTR in Q2 2013 and held it in 47 quarters. The position peaked at $77.6M in Q1 2018. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

D.E. Shaw & Co reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
D.E. Shaw & Co sold 7,679 Nektar Therapeutics shares in Q2 2025, an estimated $78.3K.
D.E. Shaw & Co first reported a position in Nektar Therapeutics in Q2 2013 and held it in 47 quarters.
D.E. Shaw & Co's Nektar Therapeutics position peaked at $77.6M in Q1 2018.
109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.